Intended for healthcare professionals

Editorials

Evidence based policy making

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7473.988 (Published 28 October 2004) Cite this as: BMJ 2004;329:988
  1. J A Muir Gray, programme director, UK National Screening Committee (muir.gray{at}ihs.ox.ac.uk)
  1. Institute of Health Sciences, University of Oxford, Oxford OX3 7LF

    Is about taking decisions based on evidence and the needs and values of the population

    Evidence based medicine or evidence based clinical practice is the judicious application of best current knowledge to the condition and values of the individual patient. Evidence can also be used for groups of patients or populations and the terms used to describe these activities vary from one document to another, sometimes being called evidence based health care, evidence based management, evidence based public health, or evidence based policy making. An example of evidence based policy making is the United Kingdom's decision to introduce screening for Down's syndrome.1 2 The common feature to all these debates is the use of evidence to make decisions about groups of patients or populations.

    Evidence based policy making sets the context in which evidence based clinical practice can take place. If the policy is not to offer screening for breast cancer to women under the age of 50, the clinician does not have to interpret the evidence about the benefits and harms of screening such women. Critics say that this is a form of rationing. Supporters say it is a process to maximise the value obtainable from the available resources. A clinician may have a view about the evidence and may need to explain to a woman who believes that it should be offered how to make her point known to the local provider of health services or local member of parliament, but no scope for evidence based clinical practice exists if the policy clearly states that a service should not be provided. This may pit the clinician against the policy maker but that can be a clear and creative tension rather than a fudge.

    Strong similarities exist between evidence based clinical practice and evidence based policy making. The first is that, in both contexts, decisions are based on evidence and not made by evidence. Secondly, in both types of decision making two other factors are present. In evidence based clinical practice the clinician has to relate the evidence to the condition of the individual patient, taking into account, for example, other risk factors or diseases that the patient may have, and then has to help the patient reflect on the options they face, taking into account their values about benefits and harms.

    In evidence based policy making, analogues of these two variables can also be seen. In evidence based policy making the policy maker has to consider the needs of the population. The evidence about breast cancer screening is the same in Hong Kong as in the United Kingdom, but because the incidence of breast cancer is much lower in Hong Kong the implication of the evidence is different. In evidence based policy making, the policy maker is rarely able to sit back and look at a single systematic review or cost benefit analysis and decide whether or not this drug or that intervention should be funded. Usually the request for funding has to be considered in the context of many other problems and demands for resources.

    Evidence based policy making would be easier if clear programme budgeting existed, so that demands such as those for increased investment in statins could be considered against other types of expenditure on cardiovascular disease, but because very few healthcare systems have programme budgeting this is rarely possible.

    Thus, and quite properly, evidence based policy making has to consider not only the evidence and needs of the population but also the values of that population. The policy debate about the development of drugs and services for patients with rare diseases highlights some of these issues of value. From the utilitarian perspective, the case for investing in common diseases is strong, but if a high value is placed on justice or fairness increased investment may be made in rare diseases, even though the cost per patient treated, and therefore the value assigned to a beneficial outcome for a patient with a rare disease, becomes, by this process, higher than the value ascribed to the same outcome for someone with a common condition. These aspects of policy making are often implicit and unstated except when economists point them out, to the unease of decision makers.

    Evidence is gathered and organised by economists, epidemiologists, and public health professionals. The needs of the population are usually described by public health professionals, but they are often hindered by the lack of programme budgeting and the dearth of good quality information about the incidence or prevalence of disease in a local population.

    Values, however, are for the public to decide or more usually by their elected representatives. This is a source of annoyance to professionals whose proposal is not funded because of a political decision, but this annoyance is usually because the politician is operating to a different set of values than the professional whose values may be based just as much on emotion as the politician's values.

    What can a professional do in this context? The job of the professional or technician is to set out all the information about the probability and size of benefits and harms, and about the opportunity costs, namely the other uses that could be made of the same amount of resources, taking into account the needs of the population. This is decision making. The job of the politician is to take the decision, as opposed to making the decision, based on values. In the end values will always be more influential than evidence, and the tension between the two should be regarded as the very stuff of the relationship between expert and politician.

    References

    1. 1.
    2. 2.
    View Abstract